U.S. infant mortality hits record low of 5.4 per 1,000 but still lags peers
Key Takeaways
- The CDC reports the U.S.
- infant mortality rate dropped to an all-time low of 5.4 per 1,000 live births in 2025, saving hundreds of lives compared to prior years.
- Yet the nation remains behind other wealthy countries, highlighting persistent gaps in maternal-child health equity and the need for targeted policy and technology-driven interventions.
Mentioned
Key Intelligence
Key Facts
- 1The U.S. infant mortality rate fell to an all-time low of 5.4 deaths per 1,000 live births in 2025, according to preliminary CDC data.
- 2Infant deaths dropped to approximately 19,350 in 2025, down from about 20,050 in 2024 and 20,160 in 2023.
- 3Three decades ago, the rate stood at 7.5 per 1,000, underscoring significant long-term improvement.
- 4The 2022 rate spike (the first in 20 years) was linked to RSV and flu rebounds; new RSV preventive measures were introduced in 2023.
- 5Despite the decline, the U.S. continues to trail other wealthy nations — the 2022 rate was nearly double that of Italy, Japan, Spain, and Sweden.
- 6The March of Dimes’ chief medical officer called the data 'an encouraging data point' but said pinpointing exact drivers is difficult.
New all-time low in U.S. infant mortality
It's difficult to pinpoint what's driving the recent developments, but this is an encouraging data point, and we hope that this trend will continue.
Remarks to MedPage Today on the 2025 data
Analysis
For healthcare providers, payers, and health IT innovators, the new CDC milestone is more than a statistic — it’s a sign that recent investments in preventive care, such as maternal RSV vaccines and expanded prenatal services, may be bending the curve. But with U.S. rates still nearly double those of peer nations, the data underscore the urgent opportunity to deploy digital health tools and value-based care models to close stubborn disparities.
The U.S. infant mortality rate reached an all-time low in 2025, with preliminary CDC data recording 5.4 deaths per 1,000 live births. This marks a modest but statistically significant decline from 5.5 in 2024 and 5.6 in the preceding two years, translating to roughly 19,350 infant deaths last year — down from about 20,050 in 2024 and 20,160 in 2023. While the numerical change appears small, public health experts emphasize that these improvements equate to hundreds of lives saved annually and represent a continuation of a decades-long trend driven by medical advances and public health interventions.
This marks a modest but statistically significant decline from 5.5 in 2024 and 5.6 in the preceding two years, translating to roughly 19,350 infant deaths last year — down from about 20,050 in 2024 and 20,160 in 2023.
Context is critical: three decades ago, the U.S. rate stood at 7.5 per 1,000. The current decline resumes progress after a concerning spike in 2022, when the rate increased for the first time in 20 years, attributed largely to a rebound of RSV and influenza following pandemic-era mitigations. In response, 2023 saw the introduction of new preventive tools: the CDC recommended an RSV vaccine for older adults, a maternal RSV vaccine to protect infants, and nirsevimab, a monoclonal antibody for babies. These measures, along with expanded prenatal care initiatives and public awareness campaigns by organizations like the March of Dimes, are likely contributing to the downward trajectory.
Despite the historic low, the United States continues to trail other high-income nations. A 2024 study found the 2022 U.S. rate was nearly double that of Italy, Japan, Spain, and Sweden. Experts point to persistent drivers: systemic poverty, unequal access to prenatal care, racial and geographic disparities, and fragmented social safety nets. The 2025 data, while encouraging, does not yet close this gap. Michael Warren, MD, MPH, chief medical and health officer of the March of Dimes, described the numbers as “an encouraging data point” and expressed hope that the trend will continue, but cautioned that pinpointing exact drivers remains difficult.
What to Watch
The market implications are multifaceted. For healthcare providers and payers, lower infant mortality signals improving maternal-child health outcomes, which can reduce long-term costs associated with neonatal intensive care and chronic conditions. For policymakers, the persistent international gap underscores the need for targeted investments in prenatal and postnatal care, particularly in underserved communities. For the health IT and medical device sectors, there is growing opportunity to support these improvements through remote monitoring, AI-driven risk assessment, and telehealth solutions that bridge access gaps.
Looking ahead, sustaining and accelerating this progress will require continued policy focus. The 2025 data may bolster arguments for extending Medicaid postpartum coverage, which many states have adopted under temporary pandemic measures but which remains inconsistent. Additionally, the full impact of RSV immunoprophylaxis may not be fully reflected yet, suggesting further declines could materialize in 2026 and beyond. However, external threats such as emerging infectious diseases, maternal health crises, and socioeconomic pressures could easily reverse gains. The U.S. infant mortality rate, while at its lowest ever, remains a barometer of broader public health equity — a metric that will demand vigilance and innovation for years to come.
Sources
Sources
Based on 2 source articles- MedPage TodayU.S. Infant Mortality Rate Falls to All-Time Low, but Trails Other Wealthy NationsJun 16, 2026
- STAT NewsThe U.S. infant mortality rate fell to an all-time low, though it still trails other similar nationsJun 16, 2026
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |